ATE187889T1 - Vorbeugung und behandlung der peripheren neuropathie - Google Patents

Vorbeugung und behandlung der peripheren neuropathie

Info

Publication number
ATE187889T1
ATE187889T1 AT93915178T AT93915178T ATE187889T1 AT E187889 T1 ATE187889 T1 AT E187889T1 AT 93915178 T AT93915178 T AT 93915178T AT 93915178 T AT93915178 T AT 93915178T AT E187889 T1 ATE187889 T1 AT E187889T1
Authority
AT
Austria
Prior art keywords
peripheral neuropathy
prevention
treatment
igf
insulin
Prior art date
Application number
AT93915178T
Other languages
English (en)
Inventor
Michael E Lewis
Stuart C Apfel
John A Kessler
Original Assignee
Cephalon Inc
Einstein Coll Med
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/051,191 external-priority patent/US5420112A/en
Application filed by Cephalon Inc, Einstein Coll Med filed Critical Cephalon Inc
Application granted granted Critical
Publication of ATE187889T1 publication Critical patent/ATE187889T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Surgical Instruments (AREA)
  • External Artificial Organs (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Apparatus For Radiation Diagnosis (AREA)
AT93915178T 1992-06-12 1993-06-01 Vorbeugung und behandlung der peripheren neuropathie ATE187889T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US89907092A 1992-06-12 1992-06-12
US08/051,191 US5420112A (en) 1992-06-12 1993-04-16 Prevention and treatment of peripheral neuropathy
PCT/US1993/005203 WO1993025219A1 (en) 1992-06-12 1993-06-01 Prevention and treatment of peripheral neuropathy

Publications (1)

Publication Number Publication Date
ATE187889T1 true ATE187889T1 (de) 2000-01-15

Family

ID=26729153

Family Applications (1)

Application Number Title Priority Date Filing Date
AT93915178T ATE187889T1 (de) 1992-06-12 1993-06-01 Vorbeugung und behandlung der peripheren neuropathie

Country Status (16)

Country Link
US (3) US5633228A (de)
EP (1) EP0659083B1 (de)
JP (1) JP3623502B2 (de)
AT (1) ATE187889T1 (de)
AU (1) AU683215B2 (de)
CA (1) CA2136969C (de)
DE (1) DE69327402T2 (de)
DK (1) DK0659083T3 (de)
ES (1) ES2140463T3 (de)
FI (1) FI945840A0 (de)
GR (1) GR3032844T3 (de)
HU (1) HU217543B (de)
NO (1) NO309705B1 (de)
NZ (2) NZ280523A (de)
PT (1) PT659083E (de)
WO (1) WO1993025219A1 (de)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU693489B2 (en) * 1993-11-15 1998-07-02 Celtrix Pharmaceuticals, Inc. Method of treating neurological disorders
US5712249A (en) * 1994-09-08 1998-01-27 Ciba-Geigy Corporation Use of insulin-like growth factors I and II for inhibition of inflammatory response
US5741776A (en) * 1995-05-22 1998-04-21 Genentech, Inc. Method of administration of IGF-I
US6420518B1 (en) 1997-04-04 2002-07-16 Genetech, Inc. Insulin-like growth factor agonist molecules
US6121416A (en) 1997-04-04 2000-09-19 Genentech, Inc. Insulin-like growth factor agonist molecules
AU746423B2 (en) * 1997-05-05 2002-05-02 Mayo Foundation For Medical Education And Research Treatment of osteoporosis
US6548482B1 (en) 1997-05-05 2003-04-15 Mayo Foundation For Medical Education And Research Treatment of osteoporosis
US6916790B2 (en) 1997-05-05 2005-07-12 Mayo Foundation For Medical Education And Research Treatment of osteoporosis
WO1999018946A1 (en) * 1997-10-14 1999-04-22 Tatton Nadine A Methods for increasing schwann cell survival
WO1999021581A1 (en) * 1997-10-28 1999-05-06 Steeves John D Immunological compositions and methods of use to transiently alter mammalian central nervous system myelin to promote neuronal regeneration
ES2146530B1 (es) * 1997-12-26 2001-04-16 Consejo Superior Investigacion Utilizacion del factor de crecimiento igf-i en la fabricacion de composiciones utiles en el tratamiento de la ataxia cerebelar.
US6043259A (en) * 1998-07-09 2000-03-28 Medicure Inc. Treatment of cardiovascular and related pathologies
PT1141014E (pt) 1999-01-06 2005-04-29 Genentech Inc Variante mutante do factor de crescimento semelhante a insulina (igf-i)
ES2250112T3 (es) 1999-03-08 2006-04-16 Medicure Inc. Analogos de piridoxal para el tratamiento de trastornos causados por carencia de vitamina b6.
US20050008641A1 (en) * 1999-04-28 2005-01-13 University Of British Columbia Composition for neuronal regeneration comprising myelin-specific antibodies and complement proteins
US6489345B1 (en) 1999-07-13 2002-12-03 Medicure, Inc. Treatment of diabetes and related pathologies
WO2001013900A2 (en) * 1999-08-24 2001-03-01 Medicure International Inc. Compositions for the treatment of cardiovascular diseases containing pyridoxal compounds and cardiovascular compounds
US6534300B1 (en) 1999-09-14 2003-03-18 Genzyme Glycobiology Research Institute, Inc. Methods for producing highly phosphorylated lysosomal hydrolases
US6770468B1 (en) 1999-09-14 2004-08-03 Genzyme Glycobiology Research Institute, Inc. Phosphodiester-α-GlcNAcase of the lysosomal targeting pathway
US6632429B1 (en) 1999-12-17 2003-10-14 Joan M. Fallon Methods for treating pervasive development disorders
US7442689B2 (en) * 2000-02-29 2008-10-28 Medicure International Inc. Cardioprotective phosphonates and malonates
AU2001237185B2 (en) 2000-02-29 2006-02-02 Medicure International Inc. Cardioprotective phosphonates and malonates
WO2001072309A2 (en) 2000-03-28 2001-10-04 Medicure International Inc. Treatment of cerebrovascular disease
ES2301547T3 (es) 2000-05-16 2008-07-01 Genentech, Inc. Tratamiento de trastornos del cartilago.
US6897228B2 (en) * 2000-07-07 2005-05-24 Medicure International Inc. Pyridoxine and pyridoxal analogues: new uses
WO2002004421A2 (en) 2000-07-07 2002-01-17 Medicure International Inc. Pyridoxine and pyridoxal analogues: cardiovascular therapeutics
US6548519B1 (en) 2001-07-06 2003-04-15 Medicure International Inc. Pyridoxine and pyridoxal analogues: novel uses
US20070053895A1 (en) * 2000-08-14 2007-03-08 Fallon Joan M Method of treating and diagnosing parkinsons disease and related dysautonomic disorders
WO2002014537A2 (en) * 2000-08-14 2002-02-21 Fallon Joan M Methods for diagnosing and treating dysautonomia and other dysautonomic conditions
US8030002B2 (en) 2000-11-16 2011-10-04 Curemark Llc Methods for diagnosing pervasive development disorders, dysautonomia and other neurological conditions
CA2399280C (en) 2000-12-13 2014-06-10 Baylor College Of Medicine Defects in periaxin associated with myelinopathies
NZ548358A (en) 2001-02-09 2008-04-30 Genentech Inc Method of identifying agonists of insulin-like growth factor-1
US20040121988A1 (en) * 2001-03-28 2004-06-24 Medicure International Inc. Treatment of cerebrovascular disease
US7714020B2 (en) * 2001-05-24 2010-05-11 Neuren Pharmaceuticals Limited Treatment of non-convulsive seizures in brain injury using G-2-methyl-prolyl glutamate
AU2002303856A1 (en) 2001-05-24 2002-12-03 Neuronz Limited Gpe analogs and peptidomimetics
US20070004641A1 (en) * 2001-05-24 2007-01-04 Neuren Pharmaceuticals Limited Cognitive enhancement and cognitive therapy using glycyl-L-2-methylprolyl-L-glutamate
US7605177B2 (en) * 2001-05-24 2009-10-20 Neuren Pharmaceuticals Limited Effects of glycyl-2 methyl prolyl glutamate on neurodegeneration
US6905856B2 (en) * 2001-12-21 2005-06-14 Genzyme Glycobiology Research Institute, Inc. Soluble GlcNAc phosphotransferase
US6800472B2 (en) * 2001-12-21 2004-10-05 Genzyme Glycobiology Research Institute, Inc. Expression of lysosomal hydrolase in cells expressing pro-N-acetylglucosamine-1-phosphodiester α-N-acetyl glucosimanidase
US20030124652A1 (en) * 2001-12-21 2003-07-03 Novazyme Pharmaceuticals, Inc. Methods of producing high mannose glycoproteins in complex carbohydrate deficient cells
ES2207387B1 (es) * 2002-02-28 2005-07-16 Consejo Sup. Investig. Cientificas Composicion quimica de igf-i para el tratamiento y prevencion de enfermedades neurodegenerativas.
US20040186077A1 (en) * 2003-03-17 2004-09-23 Medicure International Inc. Novel heteroaryl phosphonates as cardioprotective agents
US20060019929A1 (en) * 2004-07-07 2006-01-26 Albert Friesen Combination therapies employing platelet aggregation drugs
US20070060549A1 (en) * 2004-08-10 2007-03-15 Friesen Albert D Combination therapies employing ace inhibitors and uses thereof for the treatment of diabetic disorders
CN101022820A (zh) * 2004-08-30 2007-08-22 特西卡股份有限公司 诊断和治疗胰岛素样生长因子缺陷疾病的方法和装置
US20060198838A1 (en) * 2004-09-28 2006-09-07 Fallon Joan M Combination enzyme for cystic fibrosis
US7459468B2 (en) * 2004-10-28 2008-12-02 Medicure International, Inc. Aryl sulfonic pyridoxines as antiplatelet agents
US20060094749A1 (en) * 2004-10-28 2006-05-04 Medicure International Inc. Substituted pyridoxines as anti-platelet agents
CA2585165A1 (en) * 2004-10-28 2006-05-18 Medicure International Inc. Dual antiplatelet/anticoagulant pyridoxine analogs
US20080058282A1 (en) 2005-08-30 2008-03-06 Fallon Joan M Use of lactulose in the treatment of autism
US20070116695A1 (en) * 2005-09-21 2007-05-24 Fallon Joan M Pharmaceutical preparations for attention deficit disorder, attention deficit hyperactivity disorder and other associated disorders
JP2009517411A (ja) * 2005-11-28 2009-04-30 メディキュア インターナショナル インコーポレーテッド 心血管及び関連病状の処置のための調剤
US8658163B2 (en) 2008-03-13 2014-02-25 Curemark Llc Compositions and use thereof for treating symptoms of preeclampsia
US8084025B2 (en) 2008-04-18 2011-12-27 Curemark Llc Method for the treatment of the symptoms of drug and alcohol addiction
US9320780B2 (en) * 2008-06-26 2016-04-26 Curemark Llc Methods and compositions for the treatment of symptoms of Williams Syndrome
EP2318035B1 (de) * 2008-07-01 2019-06-12 Curemark, Llc Verfahren und zusammensetzungen zur behandlung von symptomen von neurologischen und geistesstörungen
US10776453B2 (en) * 2008-08-04 2020-09-15 Galenagen, Llc Systems and methods employing remote data gathering and monitoring for diagnosing, staging, and treatment of Parkinsons disease, movement and neurological disorders, and chronic pain
US20100092447A1 (en) 2008-10-03 2010-04-15 Fallon Joan M Methods and compositions for the treatment of symptoms of prion diseases
ES2668909T3 (es) 2009-01-06 2018-05-23 Galenagen, Llc Composiciones que comprenden proteasa, amilasa y lipasa para su uso en el tratamiento de infecciones por Staphylococcus aureus
US9084784B2 (en) 2009-01-06 2015-07-21 Curelon Llc Compositions and methods for the treatment or the prevention of E. coli infections and for the eradication or reduction of E. coli surfaces
US9056050B2 (en) * 2009-04-13 2015-06-16 Curemark Llc Enzyme delivery systems and methods of preparation and use
US9511125B2 (en) 2009-10-21 2016-12-06 Curemark Llc Methods and compositions for the treatment of influenza
AU2011223706A1 (en) * 2010-03-05 2012-09-20 Baylor Research Institute Involvement of androgen/androgen receptor pathway in Fabry disease
WO2012102100A1 (ja) * 2011-01-26 2012-08-02 雪印メグミルク株式会社 感覚改善剤
CN106310242B (zh) 2011-04-21 2020-02-28 柯尔马克有限责任公司 用于治疗神经精神障碍的化合物
EP2771367B1 (de) 2011-10-25 2017-12-06 Indiana University Research and Technology Corporation Gigaxoninfusionsprotein und verfahren zur behandlung von axonaler neuropathie
US10350278B2 (en) 2012-05-30 2019-07-16 Curemark, Llc Methods of treating Celiac disease
WO2018191233A1 (en) 2017-04-10 2018-10-18 Curemark, Llc Compositions for treating addiction
US11541009B2 (en) 2020-09-10 2023-01-03 Curemark, Llc Methods of prophylaxis of coronavirus infection and treatment of coronaviruses

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1275922C (en) * 1985-11-28 1990-11-06 Harunobu Amagase Treatment of cancer
SE8703625D0 (sv) * 1987-09-18 1987-09-18 Kabivitrum Ab New medical use
WO1989005822A1 (en) * 1987-12-24 1989-06-29 Gropep Pty. Ltd. Peptide analogues of insulin-like growth factor 1 (igf-1) or factor 2 (igf-2)
US5093317A (en) * 1989-06-05 1992-03-03 Cephalon, Inc. Treating disorders by application of insulin-like growth factor
EP0597033B1 (de) * 1991-08-01 1997-04-09 Genentech, Inc. IGF-I zur Verbesserung der neuronale Lage
US5420112A (en) * 1992-06-12 1995-05-30 Lewis; Michael E. Prevention and treatment of peripheral neuropathy

Also Published As

Publication number Publication date
CA2136969C (en) 2009-03-24
EP0659083A4 (de) 1996-03-20
AU4526293A (en) 1994-01-04
ES2140463T3 (es) 2000-03-01
NO944780D0 (no) 1994-12-09
HU217543B (hu) 2000-02-28
AU683215B2 (en) 1997-11-06
WO1993025219A1 (en) 1993-12-23
JP3623502B2 (ja) 2005-02-23
HUT70450A (en) 1995-10-30
US5633228A (en) 1997-05-27
FI945840A0 (fi) 1994-12-12
US5648335A (en) 1997-07-15
NO944780L (no) 1994-12-09
NZ280523A (en) 1997-07-27
NO309705B1 (no) 2001-03-19
EP0659083B1 (de) 1999-12-22
JPH07507799A (ja) 1995-08-31
EP0659083A1 (de) 1995-06-28
NZ253867A (en) 1996-08-27
DE69327402T2 (de) 2000-05-04
GR3032844T3 (en) 2000-07-31
HU9403544D0 (en) 1995-02-28
PT659083E (pt) 2000-05-31
DK0659083T3 (da) 2000-06-13
CA2136969A1 (en) 1993-12-23
DE69327402D1 (de) 2000-01-27
US5569648A (en) 1996-10-29

Similar Documents

Publication Publication Date Title
ATE187889T1 (de) Vorbeugung und behandlung der peripheren neuropathie
UA26213C2 (uk) Засіб для профілактики та лікуваhhя остеопорозу та фармацевтичhа композиція hа їх осhові
DE122009000012I1 (de) Substituierte pyrazolyl-benzolsulfonamide zur behandlung von entzundungen.
DE69406898D1 (de) Vorrichtung zur behandlung von gehirnschädigungen durch gammastrahlung und behandlungsgerät
ATE118172T1 (de) Zusammensetzung und verfahren für die behandlung von osteoporose bei säugetieren.
ATE166786T1 (de) Rapamycin zur behandlung von morbus crohn, ulcerativer colitis und ulcerative proctitis
RU94046291A (ru) Способ профилактики и лечения периферической невропатии, композиция, содержащая инсулин-подобный фактор роста i
DE69220051D1 (de) Vorrichtung zur Behandlung von Getreide
DE69304233D1 (de) Vorrichtung zur Behandlung von Wasser
DE69312853D1 (de) Behandlung von Gummiartikeln
DE69421196D1 (de) Vorrichtung zur behandlung von überbiss
DE69404785D1 (de) Vorrichtung zur Behandlung von Oberflächen
DE69527140D1 (de) Wirkstoff zur prävention oder behandlung von osteoporose
DE68917433D1 (de) Verfahren zur behandlung von asbest sowie asbestbehandlungsmittel.
ATE190843T1 (de) Zubereitungen zur behandlung von impotenz, die ein alpha-1 inhibitor und ein alpha-2 inhibitor enthalten
HUT71421A (en) Use of il-10 to prevent or treat insulin-dependent diabetes mellitus
DE69018799D1 (de) IGF-I zur Behandlung von Nebeneffekten der Steroidtherapie.
IL109419A0 (en) Enzyme compositions for the treatment of sticky cotton fiber and method for treating them with such enzyme compositions
DE69327312D1 (de) Deazaaminopterine für behandlung von entzündungen
DE59100861D1 (de) Kontinue-verfahren zur behandlung von textilen warenbahnen und entsprechende anlage.
DE69412178D1 (de) Apparat zur Behandlung von Lagen
DE69023006D1 (de) Verfahren zur behandlung von thrombocytopenie und dafür geeignete pharmazeutische zusammensetzungen.
DE69906701D1 (de) Topische verwendung von loperamid zur behandlung mikrobieller infektionen
DE3875637D1 (de) Zusammensetzungen und verfahren zur behandlung von magengeschwueren.
DE69302163D1 (de) Verfahren und Vorrichtung zur Behandlung von aktiven Elementen zur Entsorgung

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification